Jake Dunning

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4327891/publications.pdf

Version: 2024-02-01

83 papers 11,406 citations

35 h-index 76900 74 g-index

95 all docs 95 docs citations 95 times ranked 21258 citing authors

#	Article	IF	CITATIONS
1	Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ, The, 2020, 369, m1985.	6.0	2,474
2	A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases, The, 2020, 20, e192-e197.	9.1	1,165
3	Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ, The, 2020, 370, m3339.	6.0	779
4	Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infectious Diseases, The, 2022, 22, 1153-1162.	9.1	763
5	IFITM3 restricts the morbidity and mortality associated with influenza. Nature, 2012, 484, 519-523.	27.8	668
6	Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infectious Diseases, The, 2022, 22, 183-195.	9.1	585
7	Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ, The, 2020, 370, m3249.	6.0	478
8	Two cases of monkeypox imported to the United Kingdom, September 2018. Eurosurveillance, 2018, 23, .	7.0	307
9	Human-to-Human Transmission of Monkeypox Virus, United Kingdom, October 2018. Emerging Infectious Diseases, 2020, 26, 782-785.	4.3	303
10	Exportation of Monkeypox Virus From the African Continent. Journal of Infectious Diseases, 2022, 225, 1367-1376.	4.0	236
11	Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1040-1049.	5.6	216
12	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, The, 2021, 2, e354-e365.	7.3	216
13	Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nature Communications, 2022, 13, 80.	12.8	216
14	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	5.6	171
15	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Science Immunology, 2021, 6, .	11.9	161
16	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine, the, 2021, 9, 349-359.	10.7	161
17	Antiviral combinations for severe influenza. Lancet Infectious Diseases, The, 2014, 14, 1259-1270.	9.1	159
18	Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Medicine, 2016, 13, e1001997.	8.4	142

#	Article	IF	Citations
19	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine,the, 2021, 9, 699-711.	10.7	122
20	Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza. Nature Immunology, 2018, 19, 625-635.	14.5	119
21	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, The, 2021, 398, 223-237.	13.7	110
22	Rapid outbreak sequencing of Ebola virus in Sierra Leone identifies transmission chains linked to sporadic cases. Virus Evolution, 2016, 2, vew016.	4.9	105
23	Detection of SARS-CoV-2 within the healthcare environment: a multi-centre study conducted during the first wave of the COVID-19 outbreak in England. Journal of Hospital Infection, 2021, 108, 189-196.	2.9	97
24	Accumulation of Human-Adapting Mutations during Circulation of A(H1N1)pdm09 Influenza Virus in Humans in the United Kingdom. Journal of Virology, 2014, 88, 13269-13283.	3.4	84
25	Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clinical and Experimental Immunology, 2007, 150, 238-244.	2.6	83
26	Experimental Treatment of Ebola Virus Disease with Brincidofovir. PLoS ONE, 2016, 11, e0162199.	2.5	78
27	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine,the, 2021, 9, 773-785.	10.7	78
28	Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. Lancet Infectious Diseases, The, 2020, 20, 350-361.	9.1	76
29	Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. Lancet, The, 2021, 398, 1037-1038.	13.7	7 5
30	Insights from clinical research completed during the west Africa Ebola virus disease epidemic. Lancet Infectious Diseases, The, 2017, 17, e280-e292.	9.1	69
31	Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus and Viral RNA in Relation to Surface Type and Contamination Concentration. Applied and Environmental Microbiology, 2021, 87, e0052621.	3.1	62
32	M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. JCI Insight, 2017, 2, e91868.	5.0	59
33	Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients. SSRN Electronic Journal, 0, , .	0.4	56
34	Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism. Viruses, 2020, 12, 1164.	3.3	51
35	Seasonal and pandemic influenza: 100 years of progress, still much to learn. Mucosal Immunology, 2020, 13, 566-573.	6.0	50
36	Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrology Dialysis Transplantation, 2022, 37, 271-284.	0.7	48

#	Article	IF	Citations
37	Medical oaths and declarations. BMJ: British Medical Journal, 2001, 323, 1440-1441.	2.3	37
38	SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures. Thorax, 2022, 77, 259-267.	5.6	34
39	Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England. Journal of Infection, 2020, 81, 427-434.	3.3	31
40	Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. Thorax, 2022, 77, 606-615.	5.6	24
41	Patterns of systemic and local inflammation in patients with asthma hospitalised with influenza. European Respiratory Journal, 2019, 54, 1900949.	6.7	22
42	Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. BMC Health Services Research, 2021, 21, 566.	2.2	22
43	Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. The Lancet Digital Health, 2022, 4, e220-e234.	12.3	20
44	COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference. Antiviral Research, 2022, 197, 105227.	4.1	19
45	Molecular Epidemiology and Evolutionary Trajectory of Emerging Echovirus 30, Europe. Emerging Infectious Diseases, 2021, 27, 1616-1626.	4.3	18
46	A comparison of persistence of SARS-CoV-2 variants on stainless steel. Journal of Hospital Infection, 2021, 114, 163-166.	2.9	18
47	The UK's multidisciplinary response to an Ebola epidemic. Clinical Medicine, 2017, 17, 332-337.	1.9	16
48	Regulatory and Operational Complexities of Conducting a Clinical Treatment Trial During an Ebola Virus Disease Epidemic. Clinical Infectious Diseases, 2018, 66, 1454-1457.	5.8	15
49	Could expanding the covid-19 case definition improve the UK's pandemic response?. BMJ, The, 2021, 374, n1625.	6.0	14
50	SARS-CoV-2 antigen lateral flow tests for detecting infectious people: linked data analysis. BMJ, The, 2022, 376, e066871.	6.0	14
51	Persistence of SARS-CoV-2 N-Antibody Response in Healthcare Workers, London, UK. Emerging Infectious Diseases, 2021, 27, 1155-1158.	4.3	13
52	Impact of the 2009 influenza pandemic. Thorax, 2010, 65, 471-472.	5.6	11
53	Vaccine-derived rotavirus strains in infants in England. Archives of Disease in Childhood, 2020, 105, 553-557.	1.9	10
54	Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study. BMJ Open, 2021, 11, e055435.	1.9	10

#	Article	IF	CITATIONS
55	Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. Open Forum Infectious Diseases, 2022, 9, ofac179.	0.9	10
56	Influenza vaccination: lessons learned from the pandemic (H1N1) 2009 influenza outbreak. Mucosal Immunology, 2010, 3, 422-424.	6.0	9
57	Detection and Typing of Human Enteroviruses from Clinical Samples by Entire-Capsid Next Generation Sequencing. Viruses, 2021, 13, 641.	3.3	9
58	Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort. ELife, $2021,10,.$	6.0	9
59	Drug assessment in the Ebola virus disease epidemic in west Africa. Lancet Infectious Diseases, The, 2015, 15, 1258.	9.1	8
60	Human Exposures to H5N6 Avian Influenza, England, 2018. Journal of Infectious Diseases, 2019, 220, 20-22.	4.0	8
61	Pharmacokinetics of TKM-130803Âin Sierra Leonean patients withÂEbola virus disease: Âplasma concentrations exceed target levels, withÂdrugÂaccumulation in the most severe patients. EBioMedicine, 2020, 52, 102601.	6.1	7
62	Broadening symptom criteria improves early case identification in SARS-CoV-2 contacts. European Respiratory Journal, 2022, 60, 2102308.	6.7	7
63	Ebola: the battle plan must include specific treatments. Lancet, The, 2015, 385, 1373-1375.	13.7	6
64	IFITM3 restricts the morbidity and mortality associated with influenza. International Journal of Infectious Diseases, 2012, 16, e79.	3.3	5
65	Clinical Trials of Therapeutics for the Prevention of Congenital Zika Virus Disease: Challenges and Potential Solutions. Annals of Internal Medicine, 2017, 166, 725.	3.9	5
66	Novel strategies to treat antiretroviral-naive HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2009, 64, 674-679.	3.0	4
67	HIV-associated gastric natural killer/T-cell lymphoma. International Journal of STD and AIDS, 2012, 23, 66-67.	1.1	3
68	Potential adverse effects of negative publicity surrounding antivirals for influenza. BMJ, The, 2014, 348, g3015-g3015.	6.0	3
69	Early triple antiviral therapy for COVID-19. Lancet, The, 2020, 396, 1487-1488.	13.7	3
70	Treating Ebola in eastern DRC. Lancet Infectious Diseases, The, 2020, 20, 284-285.	9.1	3
71	Severe Influenza: Clinical Features and Treatment Options. Current Respiratory Medicine Reviews, 2012, 8, 208-227.	0.2	3
72	Retrospective analysis on confirmation rates for referred positive rotavirus samples in England, 2016 to 2017: implications for diagnosis and surveillance. Eurosurveillance, 2020, 25, .	7.0	2

#	Article	IF	CITATIONS
73	A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever. PLoS Neglected Tropical Diseases, 2022, 16, e0010089.	3.0	2
74	Ebola: controlling the nightmare. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2014, 108, 741-742.	1.8	1
75	Persistent norovirus outbreaks in a hospital setting – The role of environmental contamination. Journal of Infection, 2019, 79, 277-287.	3.3	1
76	Clinical lesson: old diseases may affect older patients. Journal of Infection, 2009, 59, S432-S433.	3.3	0
77	Clinical lesson: old diseases may affect older patientsCovering Letter. Journal of Infection, 2009, 59, S434.	3.3	O
78	Doctors accepting flu vaccination is the sensible and responsible choice. BMJ: British Medical Journal, 2011, 343, d7199-d7199.	2.3	0
79	The HPA H1N1 ICU Clinical Network and its role in the management of emerging diseases: Application to the critical care of patients with Pandemic influenza (H1N1) 2009 virus. Journal of Infection, 2011, 63, e3-e4.	3.3	O
80	Current research on respiratory viral infections: XIIth International Symposium. Antiviral Therapy, 2012, 17, 227-253.	1.0	0
81	The risk of sustained sexual transmission of Zika virus infection in England, United Kingdom. International Journal of Infectious Diseases, 2016, 53, 86-87.	3.3	O
82	Results of the public health follow-up of persons exposed to wild birds infected with avian influenza A(H5N6) in England, January – May 2018. International Journal of Infectious Diseases, 2019, 79, 69.	3.3	0
83	Asthma patients hospitalized with influenza lack mucosal and systemic type 2 inflammation. , 2016, , .		O